Latest news
Tango hopes it takes two: vopimetostat combos build on Revolution's pancreatic cancer breakthrough - FirstWord PharmaFirstWord Pharma · Thu, 06 Aug 2026 14:48:37 GMTIDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers - PR NewswirePR Newswire · Mon, 27 Jul 2026 10:00:00 GMT